GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » Quick Ratio

Biovica International AB (OSTO:BIOVIC B) Quick Ratio : 7.10 (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Biovica International AB's quick ratio for the quarter that ended in Jan. 2024 was 7.10.

Biovica International AB has a quick ratio of 7.10. It generally indicates good short-term financial strength.

The historical rank and industry rank for Biovica International AB's Quick Ratio or its related term are showing as below:

OSTO:BIOVIC B' s Quick Ratio Range Over the Past 10 Years
Min: 0.21   Med: 6.95   Max: 21.99
Current: 7.1

During the past 9 years, Biovica International AB's highest Quick Ratio was 21.99. The lowest was 0.21. And the median was 6.95.

OSTO:BIOVIC B's Quick Ratio is ranked better than
72.01% of 1547 companies
in the Biotechnology industry
Industry Median: 3.59 vs OSTO:BIOVIC B: 7.10

Biovica International AB Quick Ratio Historical Data

The historical data trend for Biovica International AB's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biovica International AB Quick Ratio Chart

Biovica International AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only 2.50 4.62 17.07 5.80 5.02

Biovica International AB Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.35 5.02 4.44 3.56 7.10

Competitive Comparison of Biovica International AB's Quick Ratio

For the Biotechnology subindustry, Biovica International AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biovica International AB's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biovica International AB's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Biovica International AB's Quick Ratio falls into.



Biovica International AB Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Biovica International AB's Quick Ratio for the fiscal year that ended in Apr. 2023 is calculated as

Quick Ratio (A: Apr. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(119.99-1.358)/23.638
=5.02

Biovica International AB's Quick Ratio for the quarter that ended in Jan. 2024 is calculated as

Quick Ratio (Q: Jan. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(113.006-2.633)/15.535
=7.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biovica International AB  (OSTO:BIOVIC B) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Biovica International AB Quick Ratio Related Terms

Thank you for viewing the detailed overview of Biovica International AB's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biovica International AB (OSTO:BIOVIC B) Business Description

Traded in Other Exchanges
Address
Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB (OSTO:BIOVIC B) Headlines

No Headlines